Sadly, we were informed earlier this week that a second child in Audentes Therapeutics’ AT132 gene replacement therapy clinical trial has passed away. This new loss is keenly felt by our community, and as always our heartfelt condolences go out to the bereaved families. We wish them peace and strength for the present moment and for the trying days ahead.
We know that many folks will have questions about this, so we invite families to join a community call on Zoom this Sunday to share concerns, thoughts, and questions.
The call will be Sunday, June 28th, at 7:00pm ET/6:00pm CT/4:00pm PT.
If you you are a MTM patient or family member and wish to participate, please send an email to email@example.com in advance of the call and the Zoom link will be shared directly with you.
If you missed the posts on social media, you may read the attached letter from Audentes Therapeutics by clicking the link below. While this is tragic news, Audentes spoke to the global patient organizations several days ago, and they have conveyed to us that their efforts are even more focused and motivated to ensure that AT132 reaches patients as soon and as safely as possible.